Feasibility of evidence-based diagnosis and management of heart failure in older people in care: a pilot randomised controlled trial

BMC Geriatrics

A Pali S Hungin¹  Douglas Wilson⁴  Andy Baker³  Trudy Hunt³  Mark de Belder⁵  Ahmet Fuat²  Jeremy J Murphy²  James M Mason⁴  Helen Close⁴  Helen C Hancock⁴ 

[1] School of Medicine and Health, Durham University, Queen’s Campus, Wolfson Research Institute, University Boulevard, Stockton-on-Tees, TS17 6BH, United Kingdom;Department of Cardiology, Darlington Memorial Hospital, County Durham and Darlington NHS Foundation Trust, Hollyhurst Road, Darlington, DL3 6HX, United Kingdom;Department of Cardiology, North Tees Hospital, North Tees and Hartlepool NHS Foundation Trust, Hardwick Road, Stockton, TS19 8PE, United Kingdom;Durham Clinical Trials Unit, School of Medicine, Pharmacy and Health, Durham University, Queen’s Campus, Wolfson Research Institute, University Boulevard, Stockton-on-Tees, TS17 6BH, United Kingdom;Department of Cardiology, The James Cook University Hospital, South Tees Acute Hospitals NHS Foundation Trust, Marton Road, Middlesbrough, TS4 3BW, United Kingdom

关键词: Long-term care facilities;    Older people;    Randomised controlled trial;    Treatment outcomes;    Chronic heart failure;   

Others  :  857996
DOI  :  10.1186/1471-2318-12-70

 received in 2012-10-18, accepted in 2012-10-22,  发布年份 2012

【 摘 要 】

Background

Many older people in long-term care do not receive evidence-based diagnosis or management for heart failure; it is not known whether this can be achieved for this population. We initiated an onsite heart failure service, compared with ‘usual care’ with the aim of establishing the feasibility of accurate diagnosis and appropriate management.

Methods

A pilot randomised controlled trial which randomised residents from 33 care facilities in North-East England with left ventricular systolic dysfunction (LVSD) to usual care or an onsite heart failure service. The primary outcome was the optimum prescription of angiotensin-converting enzyme inhibitors and beta-adrenergic antagonists at 6 months.

Results

Of 399 echocardiographically-screened residents aged 65–100 years, 30 subjects with LVSD were eligible; 28 (93%) consented and were randomised (HF service: 16; routine care: 12). Groups were similar at baseline; six month follow-up was completed for 25 patients (89%); 3 (11%) patients died. Results for the primary outcome were not statistically significant but there was a consistent pattern of increased drug use and titration to optimum dose in the intervention group (21% compared to 0% receiving routine care, p=0.250). Hospitalisation rates, quality of life and mortality at 6 months were similar between groups.

Conclusions

This study demonstrated the feasibility of an on-site heart failure service for older long-term care populations. Optimisation of medication appeared possible without adversely affecting quality of life; this questions clinicians’ concerns about adverse effects in this group. This has international implications for managing such patients. These methods should be replicated in a large-scale study to quantify the scale of benefit.

Trial registration

ISRCTN19781227http://www.controlled-trials.com/ISRCTN19781227 webcite

【 授权许可】

   
2012 Hancock et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Abdulla J, Køber L, Christensen E, Torp-Pedersen C: Effect of beta-blocker therapy on functional status in patients with heart failure - a meta-analysis. Eur J Heart Fail 2006, 8:522-531.
• [2]Garg R, Yusuf S: Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995, 273:1450-1456.
• [3]National Institute for Health and Clinical Excellence: Chronic heart failure: the management of adults with chronic heart failure in primary and secondary care (partial update). (Clinical guideline 108). 2010. http://www.nice.org.uk/CG108 webcite Last accessed October 2011
• [4]Lindenfeld J, Albert NM, Moser DK, Boehmer JP, Rogers JG, Collins SP, Starling RC, Ezekowitz JA, Stevenson WG, Givertz MM, Tang W, Katz SD, Teerlink JR, Klapholz M, Walsh MN: Executive Summary: Heart Failure Society of America. Comprehensive Heart Failure Practice Guideline. Heart Failure Society of America. 2010. http://www.heartfailureguideline.org/guideline_sections/41 webcite Last accessed October 2011
• [5]Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJV, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008, 29:2388-2442.
• [6]Al-Mohammad A, Mant J, Laramee P, Swain S: Diagnosis and management of adults with chronic heart failure: summary of updated NICE guidance. BMJ 2010, 341:c4130.
• [7]Waller DG, Waller JR: Beta blockers for heart failure with reduced ejection fraction. BMJ 2011, 343:d5603.
• [8]Arroll B, Doughty R, Andersen V: Investigation and management of congestive heart failure. BMJ 2010, 341:c3657.
• [9]Klarin I, Fastbom J, Wimo A: The use of angiotensin converting enzyme inhibitors and other drugs with cardiovascular effects by non-demented and demented elderly with a clinical diagnosis of heart failure. A population-based study of the very old. Eur J Clin Pharmacol 2006, 62:555-562.
• [10]Nicol E, Fittal B, Roughton M, Cleland J, Dargie H, Crowie M: NHS heart failure survey: a survey of acute heart failure admissions in England, Wales and Northern Ireland. Heart 2008, 94:172-177.
• [11]European Society of Cardiology: Task force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. Eur Heart J 2001, 22:1527-1560.
• [12]National Institute for Health and Clinical Excellence: Chronic Heart Failure. Clinical Guideline No.5. 2003-09-17. http://publications.nice.org.uk/chronic-heart-failure-cg108 webcite. Last accessed January 2010
• [13]Royal Commission on Long Term Care: With Respect to Old Age: Long Term Care - Rights and Responsibilities: A Report by the Royal Commission on Long Term Care. London: The Stationery Office. Cm4192-I; 1999. http://www.archive.official-documents.co.uk/document/cm41/4192/4192-00.htm webcite Last accessed October 2011
• [14]Howard PA, Shireman TI, Dhingra A, Ellerbeck EF, Fincham JE: Patterns of ACE Inhibitor Use in Elderly Medicaid Patients with Heart Failure. Am J Geriatr Cardiol 2002, 11:287-294.
• [15]Ahmed A, Weaver M, Allman R, DeLong J, Aronow W: Quality of care of Nursing Home Residents hospitalized with Heart Failure. J Am Geriatr Soc 2002, 50:1831-1836.
• [16]Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staeger C, Holcslaw TL, Amann-Zalan I, DeMets DL: Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomised cumulative survival (COPERNICUS) study. Circulation 2002, 106:2194-2199.
• [17]Arling ML: Outcomes of ACE inhibitor use in nursing facility residents with congestive heart failure. Ann Longterm Care 1998, 6:237-241.
• [18]Gambassi G, Lapane KL, Sgadari A, Carboni P, Gatsonis , Lipsitz LA, Mor V, Bernabei R: Effects of angiotensin converting enzyme inhibitors and digoxin on health outcomes of very old patients with heart failure. Arch Intern Med 2000, 160:53-60.
• [19]Hutt E, Frederickson E, Ecord M, et al.: Associations among processes and outcomes of care for medicare nursing home residents with acute heart failure. J Am Med Dir Assoc 2003, 4:195-199.
• [20]CIBIS-II investigators and committees: The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 1999, 353:9-13.
• [21]Houghton AR, Cowley AJ: Why are ACE inhibitors underutilised in the treatment of heart failure by General Practitioners. Int J Cardiol 1997, 59:7-10.
• [22]Ranz T, Blumenschein K, Clifton D: Prevalence and treatment of heart failure in elderly long-term care patients. Am J Health Syst Pharm 1999, 56:1334-1338.
• [23]Gambassi G, Forman D, Lapane K, Mor V, Sgardi A, Lipsitz LA, Bernabei R: Management of heart failure among very old persons living in long-term care. Has the voice of trials spread? Am Heart J 2000, 139:85-93.
• [24]Rutten FH, Grobbe DE, Hoes AW: Differences between general practitioners and cardiologists in diagnosis and management of heart failure: a survey in every-day practice. Eur J Heart Fail 2003, 5:337-344.
• [25]Horne R, Coombes I, Davies G, Hankins M, Vincent R: Barriers to optimum management of heart failure by general practitioners. Br J Gen Pract 1999, 49:353-357.
• [26]Fuat A, Hungin A, Murphy J: Barriers to accurate diagnosis and effective management of heart failure in primary care: qualitative study. BMJ 2003, 326:196.
• [27]Hobbs FDR, Jones MI, Allan TF, Wilson S, Tobias R: European survey of primary care physician perceptions on heart failure diagnosis and management (Euro-HF). Eur Heart J 2000, 21:1877-1887.
• [28]Hancock H, Close H, Mason JM, Murphy JJ, Fuat A, Singh R, Wood E, de Belder M, Brennan G, Hussain N, Kumar N, Wilson DW, Hungin APSH: High Prevalence of Undetected Heart Failure in Long-Term Care Residents: findings from the Heart Failure in Care Homes (HFinCH) study. Eur J Heart Failure 2012. in press
• [29]Folstein MF, Folstein SE, McHugh PR: Mini-Mental State. A Practical Method For Grading The Cognitive State Of Patients For The Clinician. J Psychiatr R 1975, 12:189-198.
• [30]Hodkinson HM: Evaluation of a mental test score for assessment of mental impairment in the elderly. Age Ageing 1972, 1:233-238.
• [31]Szende A, Oppe M, Devlin N: EQ-5D Value Sets: Inventory, Comparative Review and User Guide. Springer Pub; 2007. [EuroQol Group Monographs Series]
• [32]Masani N, Wharton G, Allen J, Chambers J, Graham J, Jones R, Rana B, Steeds R: Echocardiography: Guidelines for Valve Quantification. Br Soc Echocardiography Educ Committee 2009. accessed online Apri
• [33]Mason JM, Hancock HC, Close H, Murphy JJ, Fuat A, de Belder M, Singh R, Teggert A, Wood E, Brennan G, Hussain N, Kumar N, Manshani N, Hodges D, Wilson DW, Hungin APSH: Utility of biomarkers in the differential diagnosis of heart failure in older people: Findings from the Heart Failure in Care Homes (HFinCH) diagnostic accuracy study. PLOS ONE 2012. in press
• [34]The Criteria Committee of the New York Heart Association: Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th edition. Boston: Mass: Little, Brown & Co; 1994:253-256.
• [35]Schulz KF, Altman DG, Moher D, for the CONSORT Group: CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Ann Int Med 2010, 152:726-732.
• [36]Udelson JE: Heart failure with preserved ejection fraction. Circulation 2011, 124:e540-e543.
• [37]MERIT-HF study group: Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999, 353:2001-2007.